Nantes, May 23, 2022 – 7 p.m. CEST – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in precision phage therapy intended to treat resistant and/or complicated bacterial infections, announces that the general meeting meeting (AGM) of May 19, 2022 was able to validly deliberate, the quorum having been reached.
The AGM adopted all the proposed resolutions, with the exception of resolution 23 which was rejected, in accordance with the recommendations of the Council.
The shareholders of the company notably approved the evolution of the mode of management and administration of the company by adopting a Board of Directors and a General Management.
The current members of the Supervisory Board have been appointed as the first directors of Pherecydes Pharma.
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.